These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 9484499)

  • 1. Novel non-peptide fibrinogen receptor antagonists. 1. Synthesis and glycoprotein IIb-IIIa antagonistic activities of 1,3,4-trisubstituted 2-oxopiperazine derivatives incorporating side-chain functions of the RGDF peptide.
    Sugihara H; Fukushi H; Miyawaki T; Imai Y; Terashita Z; Kawamura M; Fujisawa Y; Kita S
    J Med Chem; 1998 Feb; 41(4):489-502. PubMed ID: 9484499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel non-peptide GPIIb/IIIa antagonists: synthesis and biological activities of 2-[4-[2-(4-amidinobenzoylamino)-2-(substituted)acetyl]-3-(2-methoxy-2-oxoethyl)-2-oxopiperazinyl] acetic acids.
    Kitamura S; Fukushi H; Miyawaki T; Kawamura M; Terashita Z; Sugihara H; Naka T
    Chem Pharm Bull (Tokyo); 2001 Mar; 49(3):258-67. PubMed ID: 11253914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New platelet fibrinogen receptor glycoprotein IIb-IIIa antagonists: orally active series of N-alkylated amidines with a 6,6-bicyclic template.
    Okumura K; Shimazaki T; Aoki Y; Yamashita H; Tanaka E; Banba S; Yazawa K; Kibayashi K; Banno H
    J Med Chem; 1998 Oct; 41(21):4036-52. PubMed ID: 9767641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent dibasic GPIIb/IIIa antagonists with reduced prolongation of bleeding time: synthesis and pharmacological evaluation of 2-oxopiperazine derivatives.
    Kitamura S; Fukushi H; Miyawaki T; Kawamura M; Konishi N; Terashita Z; Naka T
    J Med Chem; 2001 Jul; 44(15):2438-50. PubMed ID: 11448226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
    Guth BD; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Müller TH
    J Cardiovasc Pharmacol; 1997 Aug; 30(2):261-72. PubMed ID: 9269956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombotic effects of TAK-029, a novel GPIIb/IIIa antagonist, in guinea pigs: comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin E1 and argatroban.
    Kawamura M; Imura Y; Moriya N; Kita S; Fukushi H; Sugihara H; Nishikawa K; Terashita Z
    J Pharmacol Exp Ther; 1996 Apr; 277(1):502-10. PubMed ID: 8613960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological properties of YM-57029, a novel platelet glycoprotein IIb/IIIa antagonist.
    Moritani Y; Sato K; Shigenaga T; Hisamichi N; Ichihara M; Akamatsu S; Suzuki Ki; Nii T; Kaku S; Kawasaki T; Matsumoto Y; Inagaki O; Tomioka K; Yanagisawa I
    Eur J Pharmacol; 2002 Mar; 439(1-3):43-52. PubMed ID: 11937091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Derivatives of tetrahydroisoquinoline: synthesis and initial evaluation of novel non-peptide antagonists of the alpha(IIb)beta(3)-integrin.
    Krysko AA; Krysko OL; Kabanova TA; Andronati SA; Kabanov VM
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4444-6. PubMed ID: 20598885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of an orally active non-peptide fibrinogen receptor antagonist based on the hydantoin scaffold.
    Stilz HU; Guba W; Jablonka B; Just M; Klingler O; König W; Wehner V; Zoller G
    J Med Chem; 2001 Apr; 44(8):1158-76. PubMed ID: 11312916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and structure--activity relationship studies of a novel and specific peptide motif, Pro-X-X-X-Asp-X, as a platelet fibrinogen receptor antagonist.
    Hayashi Y; Katada J; Sato Y; Igarashi K; Takiguchi Y; Harada T; Muramatsu M; Yasuda E; Uno I
    Bioorg Med Chem; 1998 Mar; 6(3):355-64. PubMed ID: 9568289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low molecular weight, non-peptide fibrinogen receptor antagonists.
    Alig L; Edenhofer A; Hadváry P; Hürzeler M; Knopp D; Müller M; Steiner B; Trzeciak A; Weller T
    J Med Chem; 1992 Nov; 35(23):4393-407. PubMed ID: 1447740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of a series of indole glycoprotein IIb/IIIa inhibitors.
    Grumel V; Mérour JY; Lesur B; Giboulot T; Frydman A; Guillaumet G
    Eur J Med Chem; 2002 Jan; 37(1):45-62. PubMed ID: 11841874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation and pharmacological evaluation of novel glycoprotein (Gp) IIb/IIIa antagonists. 1. The selection of naphthalene derivatives.
    Ono S; Inoue Y; Yoshida T; Ashimori A; Kosaka K; Imada T; Fukaya C; Nakamura N
    Chem Pharm Bull (Tokyo); 1999 Dec; 47(12):1685-93. PubMed ID: 10748713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New orally active non-peptide fibrinogen receptor (GpIIb-IIIa) antagonists: identification of ethyl 3-[N-[4-[4-[amino[(ethoxycarbonyl) imino]methyl]phenyl]-1,3-thiazol-2-yl]-N-[1-[(ethoxycarbonyl)methyl]pip erid -4-yl]amino]propionate (SR 121787) as a potent and long-acting antithrombotic agent.
    Badorc A; Bordes MF; de Cointet P; Savi P; Bernat A; Lalé A; Petitou M; Maffrand JP; Herbert JM
    J Med Chem; 1997 Oct; 40(21):3393-401. PubMed ID: 9341914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptidomimetics - antagonists of the fibrinogen receptors: molecular design, structures, properties and therapeutic applications.
    Andronati SA; Karaseva TL; Krysko AA
    Curr Med Chem; 2004 May; 11(9):1183-211. PubMed ID: 15134514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel nonpeptide antiplatelet glycoprotein IIb/IIIa receptor antagonist, DMP754: receptor binding affinity and specificity.
    Mousa SA; Forsythe M; Lorelli W; Bozarth J; Xue CB; Wityak J; Sielecki TM; Olson RE; DeGrado W; Kapil R; Hussain M; Wexler R; Thoolen MJ; Reilly TM
    Coron Artery Dis; 1996 Oct; 7(10):767-74. PubMed ID: 8970768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GPIIb/IIIa integrin antagonists with the new conformational restriction unit, trisubstituted beta-amino acid derivatives, and a substituted benzamidine structure.
    Hayashi Y; Katada J; Harada T; Tachiki A; Iijima K; Takiguchi Y; Muramatsu M; Miyazaki H; Asari T; Okazaki T; Sato Y; Yasuda E; Yano M; Uno I; Ojima I
    J Med Chem; 1998 Jun; 41(13):2345-60. PubMed ID: 9632368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa (alphaIIb/beta3) receptor-directed platelet inhibition.
    Li YF; Spencer FA; Becker RC
    Am Heart J; 2001 Aug; 142(2):204-10. PubMed ID: 11479455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet aggregation and fibrinogen binding in human, rhesus monkey, guinea-pig, hamster and rat blood: activation by ADP and a thrombin receptor peptide and inhibition by glycoprotein IIb/IIIa antagonists.
    Cook NS; Zerwes HG; Tapparelli C; Powling M; Singh J; Metternich R; Hagenbach A
    Thromb Haemost; 1993 Sep; 70(3):531-9. PubMed ID: 8259560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arginyl-glycyl-aspartyl (RGD) epitope of human apolipoprotein (a) inhibits platelet aggregation by antagonizing the IIb subunit of the fibrinogen (GPIIb/IIIa) receptor.
    Barre DE
    Thromb Res; 2007; 119(5):601-7. PubMed ID: 16860375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.